Abstract:
:Dynamic changes in the colorectal cancer (CRC) signalome and tumor genetic heterogeneity underlie acquired drug resistance. Improving treatment-related decisions is facilitated by an emerging consensus in the classification of tumor subtypes as well as by real-time monitoring of predictive biomarkers in circulating tumor cells and DNA.
journal_name
Trends Cancerjournal_title
Trends in cancerauthors
Gargalionis AN,Papavassiliou AGdoi
10.1016/j.trecan.2017.01.003subject
Has Abstractpub_date
2017-03-01 00:00:00pages
166-168issue
3eissn
2405-8033issn
2405-8025pii
S2405-8033(17)30006-7journal_volume
3pub_type
杂志文章,评审相关文献
Trends in Cancer文献大全abstract::The repurposing of existing non-cancer drugs is a potential source of new treatment options for cancer patients with high unmet medical needs. While scientific research is progressing rapidly in the field of drug repurposing, the implementation of drug repurposing still faces important financial and regulatory hurdles...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2017.06.007
更新日期:2017-08-01 00:00:00
abstract::GLI-similar 1-3 (GLIS1-3), a subfamily of Krüppel-like zinc finger transcription factors, function as key regulators of several biological processes important to oncogenesis, including control of cell proliferation, differentiation, self-renewal, and epithelial-mesenchymal transition. This review provides a short over...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2019.07.005
更新日期:2019-09-01 00:00:00
abstract::Curative therapy for cancer patients with advanced-stage disease remains elusive. While rare outlier responses to anticancer therapies exist, barriers limit our understanding of the molecular and genetic basis of such profound, life-altering responses. Here, we describe how phenotype-to-genotype studies are elucidatin...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.11.004
更新日期:2018-01-01 00:00:00
abstract::Cancer of unknown primary (CUP) is a rare malignancy that presents with metastatic disease and no identifiable site of origin. Most patients have unfavorable features and attempts to treat based on tissue-of-origin identification have not yielded a survival advantage compared with empiric chemotherapy. Next-generation...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2020.11.002
更新日期:2021-01-27 00:00:00
abstract::TP53 is the most frequently mutated gene in breast cancer, but its role in survival is confounded by different studies concluding that TP53 mutations are associated with negative, neutral, or positive outcomes. Closer examination showed that many studies were limited by factors such as imprecise methods to detect TP53...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2020.01.007
更新日期:2020-02-01 00:00:00
abstract::Cancers develop within complex tissue environments consisting of diverse innate and adaptive immune cells, along with stromal cells, vascular networks, and many other cellular and noncellular components. The high heterogeneity within the tumor microenvironment (TME) remains a key obstacle in understanding and treating...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2020.02.022
更新日期:2020-07-01 00:00:00
abstract::Tumor heterogeneity is a large conundrum in cancer medicine, making most therapeutic interventions palliative rather than curative. Here we discuss the implications of how molecularly targeted therapies in solid malignancies that promote limited cancer cell death may in fact make tumors more heterogeneous, increase ag...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.01.010
更新日期:2020-04-01 00:00:00
abstract::Phosphoinositide 3-kinase (PI3K) generation of PI(3,4,5)P3 from PI(4,5)P2 and the subsequent activation of Akt and its downstream signaling cascades (e.g. mTORC1) dominates the landscape of phosphoinositide signaling axis in cancer research. However, PI(4,5)P2 is breaking its boundary as merely a substrate for PI3K an...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2016.05.009
更新日期:2016-07-01 00:00:00
abstract::Lactate dehydrogenase (LDH) accounts for the fermentative component of aerobic glycolysis, a near ubiquitous metabolic alteration in cancer. Recently, Oshima et al. developed a bioavailable LDH inhibitor that decreases tumor growth in mice and functions synergistically with mitochondrial respiration inhibitors. These ...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.02.012
更新日期:2020-05-01 00:00:00
abstract::The molecular basis for the clinical heterogeneity observed in patients with malignant rhabdoid tumors is unknown. Recently, two reports revealed molecular inter-tumor heterogeneity in teratoid/rhabdoid tumors (ATRTs) and extra-cranial MRTs (ecMRTs) using genomic, transcriptomic and epigenomic profiling. Distinct mole...
journal_title:Trends in cancer
pub_type: 评论,杂志文章
doi:10.1016/j.trecan.2016.04.003
更新日期:2016-05-01 00:00:00
abstract::Innate lymphoid cells (ILCs) fulfill important protective and reparative functions, and have thus been implicated in the maintenance of tissue homeostasis. Dysregulation of their activation is associated with several autoimmune and inflammatory diseases. The current literature on the role of ILCs in cancer is limited ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.03.008
更新日期:2017-05-01 00:00:00
abstract::The tumor microenvironment has an essential role in defining tumor malignancy, since it can either promote or prevent tumor initiation and subsequent progression and metastatic dissemination. Recent studies demonstrate that highly aggressive cancer cells display a high degree of metabolic plasticity paralleled by the ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2016.11.001
更新日期:2016-12-01 00:00:00
abstract::Lysophosphatidate (LPA) is emerging as a potent mediator of cancer progression in the tumor microenvironment. Strategies for targeting LPA signaling have recently entered clinical trials for fibrosis. These therapies have potential to improve the efficacies of existing chemotherapies and radiotherapy by attenuating ch...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.09.004
更新日期:2017-11-01 00:00:00
abstract::Obesity has been associated with increased severity of diagnoses for several types of cancer, and recent evidence suggests that the mechanism by which obese tissues contribute to cancer progression involves the extracellular matrix (ECM). Understanding the physicochemical differences between lean and obese ECM, and ho...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2018.02.001
更新日期:2018-04-01 00:00:00
abstract::Pancreatic ductal adenocarcinoma (PDAC) represents a major global health problem that causes over 200000 deaths each year worldwide. The disease is highly resistant to cytotoxic and targeted therapies and the average survival is less than 12 months. This situation prompted Alessandro Carugo and Giulio Draetta to devel...
journal_title:Trends in cancer
pub_type: 评论,杂志文章
doi:10.1016/j.trecan.2016.07.002
更新日期:2016-08-01 00:00:00
abstract::Epithelial-to-mesenchymal transition (EMT) determines the most lethal features of cancer, metastasis formation and chemoresistance, and therefore represents an attractive target in oncology. However, direct targeting of EMT effector molecules is, in most cases, pharmacologically challenging. Since emerging research ha...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2020.06.005
更新日期:2020-11-01 00:00:00
abstract::Alternative lengthening of telomeres (ALT) is an enigmatic process that allows certain cancers to maintain telomeres in the absence of telomerase. ALT cancers are frequently defective for ATRX/DAXX, a chaperone complex that deposits histone variant H3.3 at telomeres. We propose that mutations in alpha thalassemia-ment...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2016.02.003
更新日期:2016-03-01 00:00:00
abstract::Preclinical and clinical data emerging over the past year demonstrate that cancer cells suppress the cytotoxic functions of natural killer cells by a variety of mechanisms. These findings reveal a new arsenal of actionable therapeutic targets to drive clinically relevant immune responses against cancer. ...
journal_title:Trends in cancer
pub_type: 信件
doi:10.1016/j.trecan.2018.12.005
更新日期:2019-03-01 00:00:00
abstract::Dicer-deficient cancers have poor prognoses, which is linked to the degradation of tumour-suppressing miRNA precursors by the Translin-Trax (Tn-Tx) ribonuclease. Inhibition of Tn-Tx potentially offers a new therapeutic intervention point. However, Tn-Tx functions in an array of biological processes, and here we consid...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.02.014
更新日期:2020-06-01 00:00:00
abstract::Immuno-oncology has gained momentum thanks to the success of strategies aimed at enhancing immune-mediated antitumor response. The field of immunotherapeutic transport oncophysics investigates the physical processes that drive cancer immunotherapies. This review discusses three main aspects that determine the outcome ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2019.11.008
更新日期:2020-01-01 00:00:00
abstract::Given the implication of aberrant RAS-extracellular signal-regulated kinase (ERK) signaling in the development of a large number of tumor types, this route is under intense scrutiny to identify new anticancer drugs. Most avenues in that direction have been primarily focused on the inhibition of the catalytic activity ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2018.07.002
更新日期:2018-09-01 00:00:00
abstract::Alterations in protein ubiquitylation and hypoxia are commonly associated with cancer. Ubiquitylation is carried out by three sequentially acting ubiquitylating enzymes and can be opposed by deubiquitinases (DUBs), which have emerged as promising drug targets. Apart from protein localization and activity, ubiquitylati...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2019.08.005
更新日期:2019-10-01 00:00:00
abstract::Alternative splicing (AS) has many important roles in the pathogenesis of leukemia. Recent papers suggest that one of its key aspects is exclusion of 3'-terminal exons in favor of premature termination using intronic polyadenylation signals. This process generates leukemia suppressor isoforms with truncated C termini ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2018.10.005
更新日期:2018-12-01 00:00:00
abstract::The p90 ribosomal S6 kinase family (RSK1-4) is a group of highly conserved Ser/Thr kinases that act as downstream effectors of the Ras/Raf/MEK/ERK signaling pathway. The RSKs phosphorylate a range of substrates involved in transcription, translation, cell cycle regulation, and cell survival. Although the RSKs have a h...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.03.004
更新日期:2017-04-01 00:00:00
abstract::Although immunotherapy has proved to be effective in a variety of cancer subtypes, the role of immune checkpoint inhibition in the treatment of prostate cancer remains unclear. Here we review results from the latest clinical trials and discuss data suggesting that certain genetic mutations may confer increased sensiti...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.01.003
更新日期:2020-03-01 00:00:00
abstract::Nuclear receptors are a family of transcription factors localized in cell nuclei, sensing specific ligands and fine-tuning a variety of cell physiological events. They have been intensively investigated in cancer biology. With their excellent properties of druggability and actionability, nuclear receptors have demonst...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2020.11.007
更新日期:2020-12-16 00:00:00
abstract::The identification of STING as a key cytoplasmic innate recognition molecule for DNA viruses whose function is lost in a variety of cancers has coincided with the approval of IMLYGIC for metastatic melanoma. This represents the first replication competent viral therapy approved for the treatment of any cancer in the U...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2016.01.002
更新日期:2016-02-01 00:00:00
abstract::The rapidly evolving field of cancer immunotherapy recently saw the approval of several new therapeutic antibodies. Several cell therapies, for example, chimeric antigen receptor-expressing T cells (CAR-T), are currently in clinical trials for a variety of cancers and other diseases. However, approaches to monitor cha...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2018.03.009
更新日期:2018-05-01 00:00:00
abstract::In a recent article, Bisogno et al. reported in a randomized trial that addition of metronomic maintenance therapy (MMT) with vinorelbine plus cyclophosphamide for children with rhabdomyosarcoma resulted in a significant increase in overall and event-free survival. Although the mechanism of action remains to be fully ...
journal_title:Trends in cancer
pub_type: 评论,杂志文章
doi:10.1016/j.trecan.2019.10.004
更新日期:2019-12-01 00:00:00
abstract::In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this se...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.05.014
更新日期:2020-09-01 00:00:00